[ad_1]
Angela Merkel has done it opposed the proposal to suspend intellectual property rights for Covid-19 vaccines. The German chancellor said the limiting factors of supply were production capacities and high quality standards, not patents. “Intellectual property protection is a source of innovation and should continue to be so in the future,” he said.
Brazil could exhaust the supply of the Coronavac puncture as early as next week due to China’s shortage of critical ingredients. “Our feeling is that there are difficulties, a bureaucracy that is slower than usual with very low volume authorizations,” said Dimas Covas, head of the Butantan Institute that makes the vaccine in the country.
French President Emmanuel Macron has expressed his voice support for temporarily suspending patent protection for coronavirus vaccines. “I am totally in favor of opening up this intellectual property. I called a year ago, ”said Macron. He stressed, however, that other factors beyond prices and patents could prevent a rapid increase in global vaccine production.
Russia has approved the use of a unique feature of its Sputnik V vaccine. in a step that should expand its availability. The injection with only the first two-dose vaccine showed an effectiveness of 79.4% among Russians surveyed between December and August, the developer of the test said.
New claims for unemployment benefits in the U.S. fell below 500,000 until a new pandemic period last week. The labor department reported 498,000 initial claims for unemployment seasonally, compared to 590,000 the previous week. It was a bigger-than-expected drop, with economists looking for weekly claims of 540,000.
Regeneron reported one 38% increase in first quarter revenue as sales of its Covid-19 antibody treatment reached $ 262 million. The New York-based company said revenue rose to $ 2.5 billion in the first three months of the year, up from $ 1.8 billion in the same quarter last year.
Modern reported its first quarterly earnings and in the first three months, it sold Covid-19 vaccines worth $ 1.7 billion of the year. The drug maker said total revenue rose to $ 1.9 billion in the first quarter as it sold 102 million doses of its coronavirus vaccine. It reported a net profit of $ 1.2 billion compared to a loss of $ 124 million in the same period last year.
[ad_2]
Source link
